title: Effect of long-term aspirin use on embolic events in infective endocarditis.
abstract: BACKGROUND
  In a recent clinical trial, aspirin therapy was initiated approximately 34 days after the onset of symptoms but did not reduce the risk of embolism in patients with endocarditis. However, it is possible that aspirin used early in the course of the disease may be beneficial. The purpose of the study is to assess the effect of long-term daily aspirin use on the risk of embolic events in patients with infective endocarditis.
  
  
  METHODS
  The clinical characteristics and outcomes of patients excluded from the Multi-Centre Aspirin Trial in Infective Endocarditis because of long-term aspirin use (n = 84) were compared with the data for patients randomized to the placebo arm (n = 55). The former patients took aspirin before and during the early stages of infective endocarditis, whereas the latter patients were not exposed to aspirin before and during the entire hospitalization. Logistic modeling was used to assess the effect of long-term aspirin use on embolism and bleeding.
  
  
  RESULTS
  There was a trend toward excess bleeding in long-term aspirin recipients, compared with placebo recipients (P = .065). Logistic modeling revealed that long-term aspirin use may be associated with excess bleeding (unadjusted odds ratio, 2.35 [P = .059]; adjusted odds ratio, 2.08 [P = .118]), but it had no impact on the risk of embolic events in either model.
  
  
  CONCLUSIONS
  In patients with endocarditis, long-term daily use of aspirin does not reduce the risk of embolic events but may be associated with a higher risk of bleeding. In the acute phase of endocarditis, aspirin should be used with caution.
authors.affiliation: University of Ottawa Heart Institute, Ottawa, Ontario, Canada. kchan@ottawaheart.ca
authors.forename: Kwan-Leung
authors.initials: KL
authors.lastname: Chan
authors.forename: James
authors.initials: J
authors.lastname: Tam
authors.forename: Jean G
authors.initials: JG
authors.lastname: Dumesnil
authors.forename: Bibiana
authors.initials: B
authors.lastname: Cujec
authors.forename: Anthony J
authors.initials: AJ
authors.lastname: Sanfilippo
authors.forename: John
authors.initials: J
authors.lastname: Jue
authors.forename: Michele
authors.initials: M
authors.lastname: Turek
authors.forename: Trevor
authors.initials: T
authors.lastname: Robinson
authors.forename: Kathryn
authors.initials: K
authors.lastname: Williams
mesh_terms: D000368:Aged; D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects; D004617:Embolism / Q000209:etiology / Q000517:prevention & control*; D004697:Endocarditis, Bacterial / Q000097:blood / Q000150:complications*; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
chemical_list: D001241:Aspirin